{"database": "openregs", "table": "federal_register", "rows": [["2022-01605", "Information Requests and Discipline Review Letters Under Generic Drug User Fee Amendments; Guidance for Industry; Availability", "Notice", "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Information Requests and Discipline Review Letters Under GDUFA.\" This guidance explains how FDA will issue and use an information request (IR) and/or a discipline review letter (DRL) during the assessment of an original abbreviated new drug application (ANDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). This guidance finalizes the draft guidance of the same title issued on December 18, 2017.", "2022-01-27", 2022, 1, "https://www.federalregister.gov/documents/2022/01/27/2022-01605/information-requests-and-discipline-review-letters-under-generic-drug-user-fee-amendments-guidance", "https://www.govinfo.gov/content/pkg/FR-2022-01-27/pdf/2022-01605.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Information Requests and Discipline Review Letters Under GDUFA.\" This guidance explains how FDA will issue and use an information...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2022-01605"], "units": {}, "query_ms": 3.3268050756305456, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}